Showing 3361-3370 of 5621 results for "".
- AviadoBio and UgeneX Therapeutics Announce Agreement to Advance Gene Therapy for Retinitis Pigmentosahttps://modernod.com/news/aviadobio-and-ugenex-therapeutics-announce-agreement-to-advance-gene-therapy-for-retinitis-pigmentosa/2484165/AviadoBio and UgeneX Therapeutics announced an exclusive option and license agreement for the development and commercialization of UGX-202, an investigational AAV-based gene therapy currently in clinical development for retinitis pigmentosa (RP). The agreement
- Horizon Surgical Systems Announces World’s First Robotic Cataract Surgery Using the Polaris Platformhttps://modernod.com/news/horizon-surgical-systems-announces-worlds-first-robotic-cataract-surgery-using-the-polaris-platform/2484160/Horizon Surgical Systems announced the completion of the world’s first cataract surgery performed using its Polaris robotic platform. The milestone procedure was conducted by Uday Devgan, MD, FACS.
- EyeDura Therapeutics Partners with SERI to Advance Insulin-Based Topical Therapy for Neurotrophic Keratitishttps://modernod.com/news/eyedura-therapeutics-partners-with-seri-to-advance-insulin-based-topical-therapy-for-neurotrophic-keratitis/2484157/EyeDura Therapeutics has initiated preclinical efficacy studies in collaboration with the Singapore Eye Research Institute (SERI). The studies will advance the company’s lead insulin-based eye drop treatment for neurotrophic keratitis (NK), a rare, degen
- Regenxbio Completes Enrollment in ATMOSPHERE and ASCENT Trials of Sura-Vec Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-completes-enrollment-in-atmosphere-and-ascent-trials-of-sura-vec-gene-therapy-for-wet-amd/2484155/Regenxbio announced the completion of enrollment in its two pivotal phase 3 studies—ATMOSPHERE and ASCENT—evaluating surabgene lomparvovec (sura-vec, ABBV-RGX-314), an investigational one-time gene therapy for wet age-related macular degeneration (
- Virtual Field Launches DICOM 360 Sync Connectivity Hubhttps://modernod.com/news/virtual-field-launches-dicom-360-sync-connectivity-hub/2484151/Virtual Field announced the launch of DICOM 360 Sync, a connectivity hub that aims to redefine how practices connect diagnostics with medical records. DICOM 360 Sync is designed to deliver instant, autom
- Kalaris Therapeutics Launches Phase 1b/2 Dose-Finding Trial of TH103 for Wet AMDhttps://modernod.com/news/kalaris-therapeutics-launches-phase-1b2-dose-finding-trial-of-th103-for-wet-amd/2484144/Kalaris Therapeutics has initiated patient enrollment in a phase 1b/2 multiple ascending dose (MAD) clinical study of TH103, its investigational therapy for wet age-related macular degeneration (AMD). The phase 1b/2 t
- The Vision Council Releases Focused inSights 2025: Smart Eyewearhttps://modernod.com/news/the-vision-council-releases-focused-insights-2025-smart-eyewear/2484143/The Vision Council announced the release of 'Focused inSights 2025: Smart Eyewear,' a consumer research report that highlights growing interest and evolving attitudes toward the developing smart eyewear category. Drawing on survey responses from more than 4
- NICE Approves First NHS Treatment for Leber Hereditary Optic Neuropathy (LHON)https://modernod.com/news/nice-approves-first-nhs-treatment-for-leber-hereditary-optic-neuropathy-lhon/2484140/The UK-based National Institute for Health and Care Excellence (NICE) has approved idebenone (Raxone; Chiesi Pharmaceuticals) for the treatment of Leber Hereditary Optic Neuropathy (LHON) in patients aged 12 years and older. This marks the first time NICE has
- Inflammasome Therapeutics Reports Encouraging Early Results for K8 in Geographic Atrophyhttps://modernod.com/news/inflammasome-therapeutics-reports-encouraging-early-results-for-k8-in-geographic-atrophy/2484139/Inflammasome Therapeutics, which is developing a new class of inflammasome inhibitors known as Kamuvudines, announced promising early clinical data for its lead ophthalmic candidate K8. Delivered via a sustained-release intraocular implant, K8 reduced geograph
- Valitor Presents Preclinical Safety Data on Long-Acting Anti-VEGF VLTR-559 for Wet AMDhttps://modernod.com/news/valitor-presents-preclinical-safety-data-on-long-acting-anti-vegf-vltr-559-for-wet-amd/2484137/Valitor announced new preclinical data on VLTR-559, its long-acting anti-VEGF biologic in development for wet age-related macular degeneration (AMD). The findings were featured in a presentation at the Ophthalmology Futures Retina Forum.